Company Overview
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -181.0%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -181.02% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +244.55% |
| 6 Months: | +71.77% |
| 3 Months: | +54.44% |
| 1 Month: | +49.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)81.40 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -181.0% CAGR over 5 years.
- RSI at 81 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APGE Apogee Therapeutics, Inc. R2K | 133.96 | -30.94 | $8.29B | 0.00% | -31.41% | -28.47% | - | -181.02% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 63.10M | 73.17M | 71.28M | 78.06M | 82.77M |
| Operating Income | -1.82M | -10.51M | -12.66M | -18.89M | -24.30M | -38.18M | -44.12M | - | -63.10M | -73.17M | -71.28M | -78.06M | -82.77M |
| EBITDA | - | - | - | - | - | - | - | - | -62.89M | -72.77M | -70.87M | -77.65M | -82.36M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | -55.26M | -66.02M | -64.96M | -69.33M | -74.03M |
| Tax Provision | - | - | - | - | - | - | - | - | 83.00K | 72.00K | 61.00K | 62.00K | 79.00K |
| Net Income | -1.82M | -19.66M | -12.53M | -18.89M | -20.84M | -32.09M | -33.82M | - | -55.34M | -66.10M | -65.02M | -69.39M | -74.11M |
| Diluted EPS | -1.45 | -9.46 | -2.51 | -3.78 | -0.51 | -0.64 | -0.60 | -0.86 | -0.93 | -1.11 | -1.08 | - | -1.06 |
| R&D Expense | 1.45M | 9.88M | 8.46M | 13.95M | 17.07M | 28.72M | 33.21M | 45.71M | 46.39M | 55.70M | 54.18M | - | 60.82M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 30.73M | 93.00M | 216.87M | 285.60M |
| Operating Income | -30.73M | -93.00M | -216.87M | -285.60M |
| EBITDA | -30.64M | -93.00M | -216.68M | -284.18M |
| Interest Expense | 9.15M | 0 | - | - |
| Pretax Income | -39.78M | -83.98M | -182.13M | -255.56M |
| Tax Provision | - | 0 | 18.00K | 278.00K |
| Net Income | -39.78M | -83.98M | -182.15M | -255.84M |
| Diluted EPS | -1.46 | -3.36 | -3.30 | -3.74 |
| R&D Expense | 27.79M | 68.42M | 167.87M | 214.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 152.06M | 401.40M | 753.95M | 937.13M |
| Current Assets | 152.06M | 398.41M | 529.71M | 741.36M |
| Cash & Equivalents | 151.89M | 118.32M | 141.79M | 131.55M |
| Inventory | - | - | - | - |
| Receivables | - | 1.21M | 4.70M | 5.96M |
| Total Liabilities | 9.98M | 21.49M | 37.16M | 33.25M |
| Current Liabilities | 9.98M | 20.56M | 28.56M | 27.91M |
| Long Term Debt | - | - | - | - |
| Total Debt | 0 | 2.03M | 11.83M | 8.85M |
| Total Equity | 0 | 379.91M | 716.79M | 903.88M |
| Shares Outstanding | 48.02M | 48.52M | 59.48M | 68.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -16.43M | -74.76M | -171.17M | -227.45M |
| Investing Cash Flow | 0 | -273.91M | -300.46M | -179.57M |
| Financing Cash Flow | 168.32M | 315.39M | 495.11M | 396.49M |
| Capital Expenditure | - | -167.00K | -1.15M | -5.15M |
| Free Cash Flow | -16.43M | -74.93M | -172.33M | -232.60M |
| Net Change in Cash | 151.89M | -33.28M | 23.47M | -10.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | - | -22.1% | -25.4% | -28.3% |
| ROCE % | -21.6% | -24.4% | -29.9% | -31.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 16.64% | 10.30M | $1.37B |
| 2 | FMR, LLC | 14.96% | 9.26M | $1.23B |
| 3 | Venrock Adviser, LLC | 13.72% | 8.49M | $1.13B |
| 4 | Wellington Management Group, LLP | 7.07% | 4.38M | $583.37M |
| 5 | Blackrock Inc. | 6.60% | 4.09M | $544.70M |
| 6 | RTW Investments LP | 4.49% | 2.78M | $370.91M |
| 7 | Vanguard Capital Management LLC | 4.04% | 2.50M | $333.58M |
| 8 | Janus Henderson Group PLC | 3.81% | 2.36M | $314.71M |
| 9 | State Street Corporation | 3.49% | 2.16M | $288.37M |
| 10 | Driehaus Capital Management, LLC | 3.10% | 1.92M | $256.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APGE
What This Apogee Insider Move Might Mean After a 247% Stock Run
Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift.
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.
Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued?
Apogee Therapeutics (APGE) has attracted fresh attention after recent trading data showed sharp share price moves over the past month. This has prompted investors to reassess this clinical stage biotech’s risk and return profile. See our la…
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.…
APGE — Frequently Asked Questions
What is the current share price of Apogee Therapeutics, Inc. (APGE)?
As of 2026-07-14 21:23 PDT, Apogee Therapeutics, Inc. (APGE) trades at $133.96 on NasdaqGM. Its 52-week range is $34.65 to $133.96.
What is the market capitalisation of APGE?
Apogee Therapeutics, Inc. (APGE) has a market capitalisation of $8.29B on NasdaqGM.
What is the P/E ratio of APGE?
APGE trades at a trailing price-to-earnings (P/E) ratio of -30.94. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.24.
What is the return on equity (ROE) of APGE?
APGE has a return on equity (ROE) of -28.47%. Its return on capital employed (ROCE) is -31.41%.
Is APGE a good stock to buy?
This page provides a data-driven analysis of Apogee Therapeutics, Inc. (APGE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.